The Burrill Report


The Burrill Report (January 28, 2013): Repairing What's Broken (.MP3,19.44 Mb)

Patient advocacy groups have entered the drug development fray, mostly by providing funding for research and development for drugs they consider promising. The Myelin Repair Foundation, which is focused on developing new treatments for multiple sclerosis and related diseases, has taken a different tack in the hopes of addressing problems that make drug development today slow and expensive. We spoke to Scott Johnson, founder and CEO of the organization, about what’s wrong with drug development today, how the Myelin Repair Foundation has sought to fix it, and why their model might have implications for other disease groups.











January 24, 2013
http://www.burrillreport.com/article-repairing_whats_broken.html